Raymond L. Comenzo

17.2k total citations · 2 hit papers
230 papers, 8.3k citations indexed

About

Raymond L. Comenzo is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Raymond L. Comenzo has authored 230 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 184 papers in Molecular Biology, 114 papers in Hematology and 71 papers in Genetics. Recurrent topics in Raymond L. Comenzo's work include Amyloidosis: Diagnosis, Treatment, Outcomes (158 papers), Multiple Myeloma Research and Treatments (81 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (29 papers). Raymond L. Comenzo is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (158 papers), Multiple Myeloma Research and Treatments (81 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (29 papers). Raymond L. Comenzo collaborates with scholars based in United States, Italy and United Kingdom. Raymond L. Comenzo's co-authors include Rodney H. Falk, Martha Skinner, Morie A. Gertz, Giampaolo Merlini, Heather Landau, Giovanni Palladini, Vaishali Sanchorawala, Ashutosh Wechalekar, Angela Dispenzieri and Adam D. Cohen and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of Clinical Oncology.

In The Last Decade

Raymond L. Comenzo

219 papers receiving 8.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Systemic Amyloidoses

1997 854 citations Raymond L. Comenzo et al. profile →
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes

2012 625 citations Giovanni Palladini, Angela Dispenzieri et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Raymond L. Comenzo

Since Specialization

Citations

This map shows the geographic impact of Raymond L. Comenzo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raymond L. Comenzo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raymond L. Comenzo more than expected).

Fields of papers citing papers by Raymond L. Comenzo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raymond L. Comenzo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raymond L. Comenzo. The network helps show where Raymond L. Comenzo may publish in the future.

Co-authorship network of co-authors of Raymond L. Comenzo

This figure shows the co-authorship network connecting the top 25 collaborators of Raymond L. Comenzo. A scholar is included among the top collaborators of Raymond L. Comenzo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raymond L. Comenzo. Raymond L. Comenzo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Minimal Residual Disease Testing in Relapsed Systemic AL Amyloidosis 2024 ·Blood ·Xia Wu, (unknown), (unknown), (unknown), Vasil Mico, Ping Zhou, (unknown), Xun Ma, Raymond L. Comenzo	0
2	A Pilot Study Assessing the Accuracy of AI ChatGPT Responses for AL Amyloidosis 2024 ·European Journal Of Haematology ·(unknown), Raymond L. Comenzo, Jack Khouri, Faiz Anwer, Heather Landau, Chakra P. Chaulagain	0
3	Pooled Analysis of Safety from Birtamimab Phase 1-3 Studies in Patients with Light Chain (AL) Amyloidosis 2023 ·Blood ·Vaishali Sanchorawala, Ashutosh Wechalekar, Efstathios Kastritis, Giovanni Palladini, Stefan Schönland, Raymond L. Comenzo, Anita D’Souza, Jack Khouri, Víctor H. Jiménez‐Zepeda, (unknown), (unknown), Wenying Huang, (unknown), Morie A. Gertz	2
4	Therapeutic plasma exchange decreases plasma anti‐SARS‐CoV ‐2 spike IgG without increasing the proximate incidence of COVID ‐19 2023 ·Journal of Clinical Apheresis ·(unknown), Steven E. Conklin, (unknown), (unknown), (unknown), Raymond L. Comenzo	1
5	Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis 2022 ·JACC CardioOncology ·Monique C. Minnema, Angela Dispenzieri, Giampaolo Merlini, Raymond L. Comenzo, Efstathios Kastritis, Ashutosh Wechalekar, Martha Grogan, Ronald Witteles, Frederick L. Ruberg, Matthew J. Maurer, NamPhuong Tran, Xiang Qin, Sandra Y. Vasey, Brendan M. Weiss, Jessica Vermeulen, Arnaud Jaccard	12
6	Association between spinal stenosis and wild-type ATTR amyloidosis 2021 ·Amyloid ·Amandeep Godara, Ron I. Riesenburger, (unknown), Cindy Varga, (unknown), Nauman Siddiqui, (unknown), Andy Wang, (unknown), (unknown), (unknown), Ellen D. McPhail, Paul J. Kurtin, Jason D. Theis, (unknown), Knarik Arkun, Monika Pilichowska, James Kryzanski, Ayan R. Patel, Raymond L. Comenzo	25
7	Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study 2020 ·Journal of Clinical Oncology ·Suzanne Lentzsch, (unknown), Raymond L. Comenzo, Jeffrey A. Zonder, Keren Osman, Samuel Pan, Divaya Bhutani, (unknown), Vaishali Sanchorawala, Heather Landau	35
8	Rapid and Deep Hematologic Responses Are Associated with Improved Major Organ Deterioration Progression-Free Survival in Newly Diagnosed AL Amyloidosis: Results from Andromeda 2020 ·Blood ·Ashutosh Wechalekar, Giovanni Palladini, Giampaolo Merlini, Raymond L. Comenzo, Arnaud Jaccard, NamPhuong Tran, Huiling Pei, Sandra Y. Vasey, Brenda Tromp, Brendan M. Weiss, Jessica Vermeulen, Efstathios Kastritis	5
9	Wild-Type Transthyretin Amyloidosis Occurring in the Ligamentum Flavum of the Cervicothoracic Spine 2020 ·World Neurosurgery ·(unknown), (unknown), (unknown), (unknown), (unknown), Andy Wang, Knarik Arkun, Ayan R. Patel, James Kryzanski, Raymond L. Comenzo, Ron I. Riesenburger	10
10	Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL) 2019 ·Blood ·Angela Dispenzieri, (unknown), Ashutosh Wechalekar, Stefan Schönland, Kihyun Kım, Vaishali Sanchorawala, Heather Landau, Fiona Kwok, Kenshi Suzuki, Raymond L. Comenzo, Deborah Berg, Guohui Liu, Douglas V. Faller, Giampaolo Merlini	32
11	A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis 2017 ·Blood ·Vaishali Sanchorawala, Giovanni Palladini, Vishal Kukreti, Jeffrey A. Zonder, Adam D. Cohen, David C. Seldin, Angela Dispenzieri, Arnaud Jaccard, Stefan Schönland, Deborah Berg, Huyuan Yang, Neeraj Gupta, Ai-Min Hui, Raymond L. Comenzo, Giampaolo Merlini	101
12	Daratumumab Activity Is Agnostic to Fc Gamma Receptor 3A (FcγR3A) 158 Genotype in Patients with Primary Refractory or Relapsed Systemic AL Amyloidosis 2017 ·Blood ·(unknown), (unknown), Ping Zhou, Cindy Varga, (unknown), (unknown), (unknown), Raymond L. Comenzo	1
13	Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study 2017 ·Blood ·Ajai Chari, Saad Z. Usmani, Amrita Krishnan, Sagar Lonial, Raymond L. Comenzo, Kaida Wu, Jianping Wang, Parul Doshi, Brendan M. Weiss, Jordan M. Schecter, Andrzej Jakubowiak	23
14	First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction 2016 ·Journal of Clinical Oncology ·Morie A. Gertz, Heather Landau, Raymond L. Comenzo, David C. Seldin, Brendan M. Weiss, Jeffrey A. Zonder, Giampaolo Merlini, Stefan Schönland, Jackie Walling, Gene G. Kinney, Martin Koller, Dale B. Schenk, Spencer Guthrie, Michaela Liedtke	147
15	Immunoglobulin light chain amyloidosis 2013 ·Expert Review of Hematology ·Giampaolo Merlini, Raymond L. Comenzo, David C. Seldin, Ashutosh Wechalekar, Morie A. Gertz	71
16	A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma 2012 ·Clinical Cancer Research ·Melissa Alsina, Suzanne Trudel, Richard R. Furman, Peter J. Rosen, Owen A. O’Connor, Raymond L. Comenzo, Alvin Wong, Lori Kunkel, Christopher J. Molineaux, André Goy	119
17	The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of p53 -Mutated Multiple Myeloma Cells 2012 ·Molecular Cancer Therapeutics ·Heather Landau, Samuel McNeely, Jayasree S. Nair, Raymond L. Comenzo, Takashi Asai, (unknown), Suresh C. Jhanwar, Stephen D. Nimer, Gary K. Schwartz	48
18	Clonal Plasma Cell Pathophysiology and Clinical Features of Disease Are Linked to Clonal Plasma Cell Expression of Cyclin D1 in Systemic Light-Chain Amyloidosis 2011 ·Clinical Lymphoma Myeloma & Leukemia ·Ping Zhou, James E. Hoffman, Heather Landau, Hani Hassoun, Lakshmanan K. Iyer, Raymond L. Comenzo	24
19	Pyridone 6, A Pan-Janus–Activated Kinase Inhibitor, Induces Growth Inhibition of Multiple Myeloma Cells 2006 ·Cancer Research ·Laura Pedranzini, Tobias Dechow, Marjan Berishaj, Raymond L. Comenzo, Ping Zhou, Janeen Azare, William G. Bornmann, Jacqueline Bromberg	133
20	Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease 1992 ·The Journal of Pediatrics ·Raymond L. Comenzo, Marie E. Malachowski, H. Cody Meissner, David R. Fulton, Eugene M. Berkman	58

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact